X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will be used for production, raw material and laboratory costs associated with production of GMP cannabinoid medicines CannEpil, a high-CBD, low-THC formulation delivered by an oral mucosal solution and CogniCann, an oral spray that combines THC and CBD.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: CannEpil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oberon Capital
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Financing August 01, 2023
Details:
Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Hempstreet
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 07, 2022
Details:
The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer's disease.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: CannEpil
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sciensus Rare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 05, 2022
Details:
The study includes 150 adult patients with a confirmed SARS-CoV-2 infection, at least 4 weeks of long-COVID symptoms, and a Post Covid Functional Score (PCFS) between one and four. ArtemiC Support is administered orally, in a dosage of 5 drops three times daily for 6 weeks.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Swiss PharmaCan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswellia.
Lead Product(s): Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2021
Details:
The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.
Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Malta Enerprises
Deal Size: $3.7 million Upfront Cash: $3.7 million
Deal Type: Funding December 22, 2020
Details:
Interim Results reported to date demonstrate ArtemiCTM has met all primary end points for safety and efficacy, and FDA primary endpoint of sustained clinical recovery of COVID-19 patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation ArtemiCTM, a natural supplement formula based on Artemisinin and Curcumin (along with supporting ingredients Vitamin C and Boswellia serrata) on COVID-19 Patients.
Lead Product(s): Artemisinin,Curcumin,Frankincense
Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The Term Sheet stipulates that KS KIM will distribute ArtemiC throughout Israel, Russia, and the Commonwealth of Independent States and the countries of the Balkan region.
Lead Product(s): ArtemiC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Recipient: K S Kim International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2020
Details:
The double-blind, placebo-controlled Phase II trial will investigate the safety and efficacy of ArtemiC, a natural formulation intended for immune-modulation.
Lead Product(s): ArtemiC
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
